EGFR Transactivation is Regulated by Neurotensin Receptors in Cancer

**Moody TW**

Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA

*Corresponding author:* Terry W Moody, PhD, Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, 9609 Medical Center Doctor, Rm. 2W340, Bethesda, MD 20892, USA, Tel: +240-276-7785; E-mail: moodyt@mail.nih.gov

**Received date:** March 7, 2017; **Accepted date:** March 17, 2017; **Published date:** March 18, 2017

**Copyright:** © 2017 Moody TW. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abstract**

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) which regulates the proliferation of cancer cells especially non-small cell lung cancer (NSCLC). NSCLC growth is inhibited by EGFR tyrosine kinase inhibitors (TKI) such as erlotinib or gefitinib. Gefitinib is used to treat NSCLC patients who have EGFR mutations. EGFR tyrosine phosphorylation is regulated by G protein-coupled receptors (GPCR) such as the neurotensin (NTS) receptor. EGFR transactivation caused by NTS addition to NSCLC cells is inhibited by SR48692 (NTSR1 antagonist) or gefitinib. SR48692 and gefitinib are synergistic at inhibiting NSCLC proliferation. The results indicate that GPCR antagonists can potentiate the effects of TKI in cancer.

**Keywords:** Neurotensin; NTSR1 antagonist; SR48692; Epidermal growth factor receptor; Gefitinib; Non-small cell lung cancer

**Abbreviations**  
CNS: Central Nervous System; EGF: Epidermal Growth Factor; GPCR: G Protein-Coupled Receptor; HB: Heparin Binding; MMP: Matrix Metalloprotease; MAPK: Mitogen Activated Protein Kinase; NTS: Neurotensin; NSCLC: Non-small Cell Lung Cancer; PM: Plasma Membrane; PI: Phosphatidyl Inositol; PK: Protein Kinase; ROS: Reactive Oxygen Species; RTK: Receptor Tyrosine Kinase; SCLC: Small Cell Lung Cancer; TGF: Transforming Growth Factor; TM: Transmembrane; TKI: Tyrosine Kinase Inhibitor

**Introduction**

High concentrations of receptor tyrosine kinases (RTK) such as the Epidermal Growth Factor Receptor (EGFR, erbB1) are present in certain cancers such as non-small cell lung cancer (NSCLC) [1]. After binding ligands such as EGF, heparin binding (HB-EGF), transforming growth factor (TGF α) or amphiregulin, the EGFR can form homodimers with itself or heterodimers with other receptor tyrosine kinases (RTK) such as HER2 (erbB2) [2]. This increases tyrosine phosphorylation of protein substrates such as the mitogen activated protein kinase (MAPK) or phosphatidylinositol-3 kinase (PI3K) leading to increased cancer cellular proliferation and survival [3].

NSCLC, which kills approximately 130,000 citizens annually in the USA, is traditionally treated with combination chemotherapy; however, the 5-year survival rate is only 16% [1]. Approximately 13% of the NSCLC patients have mutated EGFR due to exon 19 deletions or exon 21 mutations such as L858R [4]. The mutated EGFR has increased tyrosine kinase activity resulting in the tyrosine phosphorylation of the EGFR. The patients with mutated EGFR can be treated with tyrosine kinase inhibitors (TKI) such as gefitinib or erlotinib, but after a year secondary EGFR mutations can occur such as T790 M resulting in TKI resistance [4]. There is a need to increase the sensitivity of NSCLC patients to TKI.

The phosphorylation of the EGFR is regulated by G protein-coupled receptors (GPCR) for neurotensin (NTS) within minutes after addition of ligand to NSCLC cells [5]. The expression of RTK such as ErbB1, ErbB2 or ErbB3 is increased by NTS days after addition to NSCLC cells [6]. The tyrosine phosphorylation of the EGFR caused by NTS addition to NSCLC cells is impaired by the NTSR1 antagonist SR48692 and the TKI gefitinib. In this communication, the mechanism by which NTS causes EGFR transactivation is reviewed.

**NTS ligand**

Neurotensin (NTS) is a 13 amino acid peptide which is biologically active in the central nervous system (CNS). When released from hypothalamic brain neurons, NTS causes analgesia, hyperthermia and modulates dopamine signaling in the CNS [7]. NTS may be a neuromodulator in the CNS whereby it is released from brain neurons and activates receptors in adjacent cells. In cancer, NTS is an autocrine growth factor. NTS is abundant in small cell lung cancer (SCLC) [8] and medullary thyroid carcinoma [9]. NTS is secreted from SCLC and binds with high affinity to SCLC cells [10]. The action of NTS is mediated by NTSR1 in cancer cells and NTS stimulates the growth of SCLC cells. SR48692 is a non-peptide NTSR1 antagonist [11] which inhibits the proliferation of pancreatic, prostate and SCLC cells in vitro and in vivo [12-14].

NTS is synthesized as a 170 amino acid precursor protein (propre-NTS) which lacks biological activity [15]. A signal protease cleaves propre-NTS to pre-NTS (147 amino acids) which is inactive. A proprotein convertase enzyme and carboxypeptidase cleaves pre-NTS to NTS (13 amino acids) which is biologically active and Neuromedin N (5 amino acids). Table 1 show that the C-terminal hexapeptide of NTS (NTS8-13) is biologically active. Degradation of NTS at the Arg8-Arg9 or Pro10-Tyr11 amide bonds by endopeptidases leads to inactive products [16]. NTS is secreted from the SCLC cells when the cellular cAMP is elevated [8]. The secreted NTS binds to cell surface receptors causing an autocrine SCLC proliferation.

**NTS receptors**

NTS binds with high affinity (Kd=4 nM) to NSCLC cells which have 1500 receptors/cell [5]. Table 1 shows that Ac-NTS8-13, NTS8-13 and SR48692 inhibit specific 125I-NTS binding with high affinity (IC50=7, 10 and 205 nM, respectively); acetylation of the N-terminal of...
NT8-13 increases its potency. In contrast, NTS1-8 and levocabastine (NTSR2 agonist) were inactive with IC50 values greater than 2000 nM. Reubi et al. [17] found a high density of specific (125I-Tyr3) NTS binding sites in Ewing’s sarcoma and medullary thyroid cancers using autoradiographic techniques. In NSCLC, NTS and NTSR1 immunoreactivity are present in approximately 60% of lung adenocarcinoma biopsy specimens [18]. NTSR1 is present in numerous cancers.

The human NTSR1 contains 418 amino acids and 7 transmembrane (TM) domains. Asn at positions 4, 37 and 41 of the NTSR1 extracellular N-terminal can be N-glycosylated whereas Cys at positions 381 and 383 of the NTSR1 intracellular C-terminal can be S-palmitoylated. SR48692 binds to a deep protein binding pocket anchored by TM6 and TM7 and numerous amino acids are essential for high affinity SR48692 binding e.g. Tyr319, Arg323, Phe326, Tyr346, Thr349, Phe353 and Tyr354 [19]. In contrast, the NT8-13-NTSR1 complex has been crystalized and NT8-13 sits on top of the NTSR1 binding pocket and binds with high affinity to Asn360, Pro361 and Tyr364 [20]. The greatest number of contacts between NTS8-13 and NTSR1 occur at extracellular loops 2 and 3 and TM domains 6 and 7. When NTSR1 is occupied by SR48692, NTS cannot bind and cause signal transduction.

**NTS signal transduction**

When activated the NTSR1 interacts with a G protein (Gq) causing phosphatidylinositol (PI) turnover in a phospholipase C dependent manner [21]. PI-4,5-bisphosphate is metabolized to inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) which elevates cytosolic Ca2+ [22] and activates protein kinase (PK)C, respectively [23]. The PKC can cause phosphorylation of ERK, PKD, focal adhesion kinase and Src [24-27]. In a ligand independent mechanism, Src can directly phosphorylate the EGFR at Tyr845 [28]. In the triple membrane passing signal pathway, NTSR1 activation causes shedding of EGFR ligands from the plasma membrane (PM). Matrix metalloproteases (MMP) of the disintegrin and metalloproteinase (ADAM) family cleave inactive precursors e.g. the 160 amino acid prepro-TGF α in the kinase RAF leading to the activation of MEK which phosphorylates ERK. Phosphorylated ERK enters the nucleus and increases expression of the nuclear oncogenes c-fos and c-jun after 1 hour. NTS addition to glioblastoma cells up-regulates c-myc but down regulates mir-29b-1 and mir-129-3p [29]. The c-fos and c-jun form heterodimers and increase expression of growth factor genes such as neurotensin/neuromedin N [30].

**RTK transactivation**

NTS analogs were added to NCI-H1299 NSCLC cells and the tyrosine phosphorylation of the EGFR determined by Western blot. (Figure 1A and 1B) shows that addition of NTS to NSCLC cells increases P-EGFR significantly after 0.5 min and the effect is maximal after 2 min. In contrast, NTS has no effect on total EGFR after 2 min. The effect of NTS on P-EGFR is dose-dependent and half-maximal tyrosine phosphorylation of the EGFR occurs using 5 nM NTS (Figure 1C and 1D). Structure-activity studies showed that NTS, Ac-NTS8-13, NTS8-13 but not NTS8-1 increase phosphorylation of the EGFR (Figure 1E and 1F). Addition of NTS to NSCLC cells for 2 min increased tyrosine phosphorylation of the EGFR 3-fold which was inhibited by SR48692, siRNA for NTSR1 and gefitinib [5]. Addition of JMV449, a NT8-13 analog, to NSCLC cells for 48 hours increased expression of EGFR, HER2 and HER3 approximately 2-fold [6]. Also, JMV449 increased P-EGFR, P-HER2 and P-HER3 which was reversed by SR48692. JMV449 increased MMP1 resulting in elevated HB-EGF and Neuregulin-1 which activate the EGFR and HER3, respectively.

**Figure 1:** Regulation of EGFR transactivation by NTSR1. (A) The ability of 100 nM NTS to increase tyrosine phosphorylation of the EGFR in NSCLC cells was investigated as a function of time. Total EGFR was unaltered. (B) The mean P-EGFR+S.D. of 3 determinations is indicated; p<0.05*, p<0.01** by ANOVA. (C) The ability of NTS to increase tyrosine phosphorylation of the EGFR in NSCLC cells at 2 min was investigated as a function of dose. Total EGFR was unaltered. (D) The mean P-EGFR+S.D. of 3 determinations is indicated; p<0.01** by ANOVA. (E) The ability of 100 nM NTS, NTS8-13, NTS8-1 or Ac-NTS8-13 to increase tyrosine phosphorylation of the EGFR in NSCLC cells was investigated after 2 min. Total EGFR was unaltered. (F) The mean P-EGFR+S.D. of 3 determinations is indicated; p<0.01** by ANOVA.

Reactive oxygen species (ROS) are essential for NTS to cause EGFR transactivation. GPCR may cause p47phox phosphorylation leading to the activation of NADPH oxidase increasing ROS [31]. The ROS
may oxidize protein tyrosine phosphatases reducing catalytic activity resulting in a transient increase in EGFR tyrosine phosphorylation [28]. The transactivation of the EGFR regulated by NTSR1 is impaired by Tiron (superoxide scavenger) and diphenylethionide (NADPH oxidase inhibitor) [5].

NTS causes EGFR transactivation in numerous cancers including prostate cancer, colon cancer and foregut neuroendocrine tumors [23,32,33]. Gastric cancer patients whose tumors had high levels on NTSR1 immunoreactivity had poor patient survival [34]. Addition of NTS to NSCLC cells caused tyrosine phosphorylation of the EGFR, Src and β-catenin in a PKC-dependent manner [5]. When β-catenin is phosphorylated, it dissociates from E-Cadherin and enters the nucleus altering gene expression of the NTSR1. In hepatocellular carcinoma, NTSR1 expression is reduced by methylation of the NTSR1 gene is associated with increased patient survival [37]. NTSR1 expression is reduced in colorectal cancer cell lines resulting in decreased proliferation [38]. These results indicate that NTSR1 levels can be regulated by epigenetic mechanisms.

Proliferation

The NTSR1 regulates the proliferation of NSCLC cells. Addition of NTS stimulated the proliferation of NSCLC cells whereas SR48692 inhibits the proliferation of NSCLC cells in a cytostatic manner (Table 1). SR48692 potentiated the cytotoxicity of gefitinib in a synergistic manner [5]. Breast cancer tumors grew faster in nude mice if they had high levels of NTS [36]. Tumors with high levels of NTS had elevated EGFR, HER2 and HER3 and their phosphorylated derivatives. The high levels of P-EGFR, P-HER2 and P-HER3 were reversed if the mice were treated with SR48692. The breast tumors with elevated NTS had increased MMP9 resulting in increased secretion of HB-EGF and Neuregulin-2. Approximately 43% of the biopsy specimens from NSCLC patients had immunostaining for NTSR1. The survival of NSCLC patients who had high NTSR1 levels was significantly reduced relative to NSCLC patients whose tumor had low levels of NTSR1 [6]. It remains to be determined if SR48692 will potentiate the effects of TKI in NSCLC patients. The NTSR1 gene is present in many colon cancer biopsy specimens. Methylation of the NTSR1 gene is associated with increased patient survival [37]. NTSR1 expression is reduced by histone deacetylase inhibitors in colorectal cancer cell lines resulting in decreased proliferation [38]. These results indicate that NTSR1 levels can be regulated by epigenetic mechanisms.

<table>
<thead>
<tr>
<th>Ligand</th>
<th>IC50, nM</th>
<th>% Proliferation</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTS</td>
<td>4±1</td>
<td>176±19</td>
</tr>
<tr>
<td>Ac-NTS8-13</td>
<td>7±1</td>
<td>157±16</td>
</tr>
<tr>
<td>NTS8-13</td>
<td>10±3</td>
<td>143±18</td>
</tr>
<tr>
<td>SR48692</td>
<td>205±31</td>
<td>48±7</td>
</tr>
<tr>
<td>NTS1-8</td>
<td>&gt;2000</td>
<td>103±11</td>
</tr>
<tr>
<td>Levocabastine</td>
<td>&gt;2000</td>
<td>102±12</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>&gt;2000</td>
<td>62±8</td>
</tr>
<tr>
<td>None</td>
<td>ND</td>
<td>100±7</td>
</tr>
<tr>
<td>SR4869+Gefitinib</td>
<td>ND</td>
<td>23±5</td>
</tr>
</tbody>
</table>

Table 1: Effect of ligands on NSCLC cells The IC50±S.E. of 3 determinations to inhibit specific 125I-NTS binding to NSCLC cells are indicated. The % mean colony number±S.E. of 3 determinations is indicated using NSCLC cells; P<0.05, P<0.01” by ANOVA. The ligand structures are shown below: (1) NTS: Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu. (2) SR48692: 2-[1-(7-chloro-4-quinolinyl)-5-(2,6)-dimethoxyphenyl]-1H-pyrazole-3-yl-carboxy[amino]tricyclo[3,3,1,13]decane-2-carboxylic acid. (3) Gefitinib N-(3-chloro-4-fluoro-phenyl)-7-methoxy-(3-morpholin-4-ylpropoxy) quinazoline-4-amine.

Conclusion

Gefitinib and erlotinib are currently used to treat NSCLC patients who have failed chemotherapy and have EGFR mutations. Due to low potency TKI are not used in patients with wild type EGFR. The potency of gefitinib can be increased in cells with wild type EGFR using GPCR antagonists such as SR48692 [5]. The NTSR1 is an excellent molecular target in cancer and its expression in NSCLC, breast and gastric tumors is associated with poor patient survival.

There are multiple GPCR in cancer cells which can regulate RTK transactivation. Peptide GPCR include angiotensin, bombesin, bradykinin, cholecystokinin, endothelin, pituitary adenylate cyclase activating peptide and substance P, all of which interact with Gq and cause PI turnover [39]. RTK which can be transactivated include erbB1, erbB2, erbB3, platelet derived growth factor receptor and Trk. There are numerous GPCR antagonists which may potentiate the ability of TKI to inhibit the growth of cancer cells.

Acknowledgements

The author thanks Dr. R. Jensen for helpful discussion. This research is supported by the NCI intramural program of the NIH.

References


Arch Sci, an open access journal


